JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma

Table 3

Correlation of JAK3/TYK2 mRNA expression and first progression in STAD with different clinicopathological factors (Kaplan–Meier plotter).

Pathological parameters	First progression
	JAK3			TYK2
		Hazard radio	value		Hazard radio	value
Sex
Female	201	2.02 (1.38-2.95)	0.00021	201	1.37 (0.94-2)	0.097
Male	437	1.42 (1.1-1.84)	0.0076	437	2.07 (1.6-2.68)
Stage
1	60	2.37 (0.79-7.1)	0.11	60	0.54 (0.18-1.68)	0.28
2	131	1.5 (0.79-2.84)	0.21	131	1.42 (0.77-2.61)	0.25
3	186	1.52 (1.04-2.24)	0.031	186	1.36 (0.94-1.97)	0.1
4	141	0.64 (0.41-1.02)	0.057	141	0.73 (0.48-1.11)	0.14
Stage T
2	239	1.51 (0.92-2.45)	0.097	239	1.21 (0.8-1.83)	0.36
3	204	0.7 (0.49-1.01)	0.054	204	1.35 (0.9-2.02)	0.15
4	39	0.46 (0.2-1.09)	0.072	39	0.77 (0.36-1.66)	0.5
Stage N
0	72	2.22(0.66-7.49)	0.19	72	1.56 (0.66-3.65)	0.3
1	222	2.27 (1.34-3.82)	0.0016	222	1.45 (0.98-2.15)	0.059
2	125	0.84 (0.53-1.32)	0.44	125	0.59 (0.38-0.91)	0.015
3	76	1.31 (0.72-2.37)	0.37	76	0.73 (0.41-1.33)	0.3
1+2+3	423	1.32 (1-1.74)	0.049	423	0.89 (0.67-1.17)	0.4
Stage M
0	443	1.35 (0.98-1.85)	0.066	443	1.21 (0.92-1.59)	0.17
1	56	0.6 (0.33-1.11)	0.099	56	0.41 (0.19-0.92)	0.026
Lauren classification
Intestinal	263	1.74 (1.15-2.62)	0.0078	263	1.28 (0.88-1.88)	0.2
Diffuse	231	1.25(0.87-1.79)	0.22	231	0.85 (0.59-1.24)	0.4
Differentiation
Poor	121	1.32 (0.84-2.09)	0.23	121	0.67 (0.41-1.08)	0.095
Moderate	67	0.63 (0.33-1.19)	0.15	67	0.6 (0.32-1.13)	0.11